Cure, a premier healthcare innovation ecosystem headquartered in New York City, released the The Future of Healthcare Innovation 2025, a landmark report capturing the surprising results of a CEO survey that shows despite policy shifts and funding uncertainty, 87 percent of healthcare leaders remain optimistic about the future of the biotech industry. The report, reflecting opinions, concerns, and strategies of leading entrepreneurs, investors, academics, and government stakeholders, paints a picture of an industry evolving in real-time and meeting the moment not with paralysis but with purpose and ingenuity.
"Disruption can be a powerful catalyst for change — entrepreneurs are adapting, not retreating," said Seema Kumar, CEO of Cure. "The data and insights captured in The Future of Healthcare Innovation 2025 reveal that healthcare leaders are responding with bold ideas and smart pivots to rethink how breakthroughs can move from discoveries into real-world impact."
Cure developed the report using data from a May 2025 Cure survey of more than 100 CEOs and senior executives across the healthcare sector and interviews with select leaders. Cure conducted this survey in partnership with the Deerfield Institute, a division of Deerfield Management Company, an affiliate of Cure.
How are Healthcare Leaders Navigating This Moment of Uncertainty?
The top 10 findings from Cure's report include: